Sarcopenia: a new issue in juvenile idiopathic arthritis. A study Protocol


Hanene Lassoued Ferjani
Fatma Majdoub
Dorra Ben Nessib
Dhia Kaffel
Wafa Triki
Kaouther Maatallah
Wafa Hamdi


Background : The decrease in muscle function and mass is defined as sarcopenia. Known for a long time as an age-related disorder, sarcopenia
is nowadays well recognized in childhood. Juvenile idiopathic arthritis (JIA), a chronic inflammatory joint disease may be associated with loss of
skeletal mass.
Objective : This protocol aims to evaluate the prevalence rate of sarcopenia and its associated factors in JIA.
Methods : To evaluate the prevalence rate and factors associated with sarcopenia in juvenile idiopathic arthritis, we are enrolling 30 children with
JIA and 30 healthy children aged between 4-and 16 years. Clinical data will report: age, sex, body mass index, disease duration, and therapeutic
management. All participants will undergo the Whole-body Dual-energy X-ray absorptiometry to assess the skeletal muscle mass. The muscle
strength will be measured using the handgrip dynamometer and adjusted to the body mass index. Data will be analyzed and compared to age and
sex reference curves.
Results : This study aims to detect sarcopenia in JIA children and identify subsequently the main associated factors. By collecting anthropometric
data and extracting the main features of the disease, specific metrics will be extracted. Body composition will be obtained using the DXA scans,
including appendicular lean mass and skeletal muscle mass. Muscle strength will also be assessed.
Conclusion : This study aims to assess sarcopenia in JIA patients, using the sarcopenia update definition. If we will provide conclusive results, it
will be possible to better identify the associated factors of sarcopenia and to prevent children from this complication.
Clinical trials registration NCT05291416


Sarcopenia, Juvenile Idiopathic Arthritis, Dual-energy X-ray absorptiometry



  1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16‑31.
  2. McCarthy HD, Samani-Radia D, Jebb SA, Prentice AM. Skeletal muscle mass reference curves for children and adolescents. Pediatric Obesity 2014;9(4):249‑59.
  3. Houghton KM, Macdonald HM, McKay HA, Guzman J, Duffy C, Tucker L, et al. Feasibility and safety of a 6-month exercise program to increase bone and muscle strength in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2018;16(1):67.
  4. Foeldvari I, Bidde M. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol 2000;27(4):1069‑72.
  5. Webber CE, Barr RD. Age- and gender-dependent values of skeletal muscle mass in healthy children and adolescents. J Cachexia Sarcopenia Muscle 2012;3(1):25‑9.
  6. Kim J, Shen W, Gallagher D, Jones A, Wang Z, Wang J, et al. Total-body skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in children and adolescents-. Am J Clin Nutr 2006;84(5):1014‑20.
  7. An HJ, Tizaoui K, Terrazzino S, Cargnin S, Lee KH, Nam SW, et al. Sarcopenia in Autoimmune and Rheumatic Diseases: A Comprehensive Review. Int J Mol Sci 2020;21(16):E5678.
  8. Dzhus M, Kulyk M, Karasevska T. Pos1315 Prevalence of Sarcopenia in Young Adults with Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases 2022;81(Suppl 1):995‑995.
  9. Bone AE, Hepgul N, Kon S, Maddocks M. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis 2017;14(1):85‑99.
  10. Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V, et al. Sarcopenia and Heart Failure. Nutrients 2020;12(1):E211.
  11. Little RD, Prieto-Potin I, Pérez-Baos S, Villalvilla A, Gratal P, Cicuttini F, et al. Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis. Sci Rep. 2017;7(1):6311.
  12. Mochizuki T, Yano K, Ikari K, Okazaki K. Sarcopenia-associated factors in Japanese patients with rheumatoid arthritis: A cross-sectional study. Geriatr Gerontol Int. 2019;19(9):907‑12.
  13. Torii M, Hashimoto M, Hanai A, Fujii T, Furu M, Ito H, et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(4):589‑95.
  14. Ngeuleu A, Allali F, Medrare L, Madhi A, Rkain H, Hajjaj-Hassouni N. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int. 2017;37(6):1015‑20.
  15. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994;93(6):2379‑86.
  16. Aguiar R, Sequeira J, Meirinhos T, Ambrósio C, Barcelos A. SARCOSPA - Sarcopenia in spondyloarthritis patients. Acta Reumatol Port. 2014;39(4):322‑6.